Abstract: The present disclosure relates to anti-Muscle-Specific Kinase (MuSK) antibodies, in particular agonistic ant-MuSK antibodies, useful to restore or increase the function of the neuromuscular junction (NMJ).

Abstract: The present disclosure relates to antibodies that bind the extracellular domain of human TREM2 and the use of anti-TREM2 antibodies in therapy, prophylaxis, diagnosis, screening, and monitoring, including for increasing levels of soluble TREM2 (sTREM2) in serum and brain, increasing phagocytosis by microglia and/or macrophages, and developing treatments to address TREM2-mediated conditions that may benefit from enhanced phagocytosis by microglia and/or macrophages.

Abstract: The present disclosure relates to antibodies that bind the extracellular domain of human TREM2 and the use of anti-TREM2 antibodies in therapy, prophylaxis, diagnosis, screening, and monitoring, including for increasing levels of soluble TREM2 (sTREM2) in serum and brain, increasing phagocytosis by microglia and/or macrophages, and developing treatments to address TREM2-mediated conditions that may benefit from enhanced phagocytosis by microglia and/or macrophages.

Abstract: A CTC-based train operation adjustment method and apparatus are provided. The adjustment apparatus includes a TDMS system interface server, a TD combined and shared intermediate database, a CTC system, a TD combined interface server and the like. The CTC system further includes a CTC system communication server, a running diagram platform and the like.

Abstract: Provided in the present invention is a pharmaceutical composition comprising hydroxyprogesterone caproate and an additional therapeutic agent for treating tumors, wherein the additional therapeutic agent is preferably a monoclonal antibody against PD-1 or PD-L1. Further provided in the present invention are a method for increasing the number of tumor infiltrating lymphocytes (TIL) as required and a method for treating cancers in a subject in need thereof, which comprises providing the hydroxyprogesterone caproate to the subject.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Using artificial intelligence (AI)-based techniques to detect glitches in audiovisual data can improve the reliability of glitch detection and reduce the cost of system validation and/or maintenance. An AI-based method for detecting glitches in an image can include extracting one or more features from the image; providing the image and the extracted features as inputs to a model; and generating, by the model, a classification output indicating whether the image is glitched. An AI-based method for detecting glitches in an audio data segment can include generating an image including a spectrogram of the audio data segment; providing, the image as input to a model; and generating, by the model, a classification output indicating whether the audio data segment represented by the image is glitched. Records of the glitches can be generated, and the validation status of a system-under-test (SUT) can be determined based on the records.

Abstract: A connector includes a base and a sliding elastic sheet. The base includes a bottom portion, a first extending portion, a second extending portion, and a wing portion. The first extending portion and the second extending portion protrude from the bottom portion. The first extending portion and the second extending portion are arranged in a direction. The wing portion laterally extends from the bottom portion and located between the bottom portion and one of the first extending portion and the second extending portion. The sliding elastic sheet is slidably disposed on the base. The sliding elastic sheet includes at least one engaging portion, and the sliding elastic sheet is engaged with the base by the at least one engaging portion. The sliding elastic sheet moves relative to the base between a first state and a second state different from the first state.

Abstract: A method for co-administrating hydroxyprogesterone caproate, tyrosine kinase inhibitor, and/or anti-PD-I/PD-LI an-1 tibodies for tumor treatment. The present application also provides a corresponding pharmaceutical use and a pharmaceutical product. Co-administration with hydroxyprogesterone caproate can further improve the therapeutie effect of lenvatinib and anti-PD-I/PD-L1 antibodies against tumors.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism and myeloproliferative disorders using anti-TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.

Abstract: An oral preparation containing a progestogen, and a preparation method and the use. The oral preparation does not contain or contains only benzyl benzoate in a weight percentage of less than 8%. The preparation contains 17-? hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, and propylene glycol monolaurate. The oral preparation provides good stability, dissolution performance, and bioavailability while ensuring high safety.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.